MSB 2.08% 94.0¢ mesoblast limited

"Mesoblast expects to receive feedback from the FDA in the...

  1. 5,794 Posts.
    lightbulb Created with Sketch. 2103
    "Mesoblast expects to receive feedback from the FDA in the current quarter on the potential pathways to US regulatory approval for its rexlemestrocel-L technology platform following the recently completed Phase 3 trials in patients with chronic heart failure and chronic low back pain (CLBP) due to degenerative disc disease "

    Does this mean those meetings have already taken place?

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
94.0¢
Change
-0.020(2.08%)
Mkt cap ! $1.073B
Open High Low Value Volume
95.5¢ 97.0¢ 93.5¢ $1.424M 1.507M

Buyers (Bids)

No. Vol. Price($)
8 29390 93.5¢
 

Sellers (Offers)

Price($) Vol. No.
94.5¢ 14089 2
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.